晚期肺鳞状细胞癌内科治疗研究进展

Research progress of the medicine treatment of advanced lung squamous cell carcinoma

近十年来,以表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）为代表的靶向药物为肺腺癌的治疗带来了突破性进展,然而肺鳞状细胞癌的治疗却进入瓶颈期.2012年有研究表明抗程序性死亡受体-1（PD-1）/PD-1配体（PD-L1）抗体对非小细胞肺癌（NSCLC）有效且安全性优于化疗,2015年美国食品与药品监督管理局（FDA）批准抗PD-1抗体nivolumab用于治疗晚期肺鳞状细胞癌,掀起了免疫靶向药物治疗NSCLC的热潮.文章将对晚期肺鳞状细胞癌的治疗进展从化疗、靶向治疗、免疫靶向治疗三方面进行综述.

In the last decade,many molecular targeted drugs,such as epidermal growth factor receptor-tyrosine kinase inhibitor （EGFR-TKI）,have been successively applied in clinical use,and they have brought about a substantial prolongation of survival life and improvement in life quality of those patients with lung adenocarcinoma,but that is not real in squamous cell lung cancer.Immunotherapy clinical trials for programmed death receptor-1 （PD-1）/programmed death ligand-1 （PD-L1） pathway in non-small cell lung cancer （NSCLC） have been started since 2012.In 2015,an anti-PD-1 antibody,nivolumab,was proved by FDA to treat advanced squamous NSCLC with progression on or after platinum-based chemotherapy.This article reviews the recent advantages in the treatment of advanced lung squamous cell carcinoma.